-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
July 23, NMPA publish this document, Shenzhou Cell Engineering "recombinant human coagulation factor Ⅷ" (codename: SCT800) approved the listing, is indicated for hemophilia hemorrhage control and prevention
From: NMPA official website
Hemophilia A is a coagulation dysfunction caused by the lack of coagulation eight factor protein.
2018, the number of patients with hemophilia worldwide about 774,000, the number of patients in China about 14 million, of which about 85% of the hemophilia patients
Factor VIII is a special medicine and essential medicine for patients with hemophilia A.
The eight factors of coagulation in China are mostly extracted from human plasma, but due to the shortage of human plasma supply, the production capacity of plasma to extract the eight factors is very limited
From the Insight database (http://db.